Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

Novo Nordisk

Status and phase: Terminated; Phase 2

Conditions: Malignant Melanoma; Cancer

Treatments: Drug: recombinant interleukin-21

Study type: Interventional

Funder types: Industry

Identifiers

NCT00601861

NN028-1801

2006-005350-79 (EudraCT Number)

Details and patient eligibility

About

The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma

Full description

The decision to discontinue the NN028-1801 trial is not due to any safety concerns. The trial was terminated as a result of a strategic decision by the sponsoring company.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage III melanoma
• ECOG performance status 0-1

Exclusion criteria

• Signs of stage IV melanoma
• Safety variables

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

A

Experimental group

Treatment:

Drug: recombinant interleukin-21